Navigation Links
Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Date:9/23/2009

RICHMOND, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania. Both Phase 1 studies are designed primarily to evaluate the safety and tolerability of this ZFP Therapeutic(TM) approach, however subjects' CD4 T-cell counts, levels of CCR5-modified T-cells and viral burden will also be monitored.

"Opening a second Phase 1 clinical trial of this exciting new approach to HIV/AIDS treatment enables us to expedite clinical and commercial development of SB-728-T. We are very pleased with the FDA's decision enabling us to expand this program and move forward quickly with a repeat-dosing trial," said Dale Ando, M.D., Sangamo's chief medical officer and vice president of therapeutic development.

"The best approach to controlling HIV is by preventing infection of cells in the first place. Since 1996, when CCR5 was validated as a target for HIV therapy, the goal has been to recapitulate the naturally-occurring protection against viral infection exhibited by individuals who have the CCR5-delta32 mutation. We have the ability to disrupt the CCR5 gene and make human T-cells resistant to infection by CCR5-specific strains of HIV. In this trial we will be evaluating SB-728-T in subjects that have well-controlled levels of virus but have sub-optimal recovery of CD-4+ T-cell counts despite long-term triple drug therapy. This group represents approximately thirty per
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
2. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
3. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
4. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
7. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
8. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
9. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
10. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
11. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 ... DMPI) ("DelMar" "the Company") today announced the filing of ... recently changed its fiscal year end to June 30th ... common stock on a national securities exchange in the ... filed with the United States Securities Exchange Commission can ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... 1, 2012 Heart IT, the global leader ... medical imaging workstation, WebPAX®, announced today the award ... viewing technologies. "Zero-footprint" technologies allow health care professionals ... with a standard Internet web browser. ...
... (NASDAQ: ANGN ) today announced it has ... Global Sales effective May 7, 2012. Mr. Margolies will ... worldwide sales organization and delivering sales results to achieve ... Mr. Margolies will be succeeding James Gaul, senior vice ...
Cached Medicine Technology:U.S. Patent Office Issues Sixth Patent Covering 'Zero-Footprint' Medical Image Viewers to Heart Imaging Technologies, LLC 2Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales 2Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales 3Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales 4
(Date:9/1/2014)... Beginning Tuesday, September 2nd, Las Vegas will ... 10,000 consumers for the annual gathering known as Pain ... nation’s top medical professionals who specializes in chronic pain ... event contains more than 120 hours of the most ... pain management field. , MarijuanaDoctors.com is pleased to announce ...
(Date:8/31/2014)... MYMOBILEUNI (MMU) strategy is to outreach ... tools access to digital, resources, courses, videos, audio ... tools to reach and collaborate with educational institutions ... channels. , MMU, today announced the availability of ... that applies social networking concepts to the learning ...
(Date:8/31/2014)... (PRWEB) September 01, 2014 GoDaddy, ... companies that provide VPS (Virtual Private Server) hosting, ... server computer into many servers, each of which ... someone’s own dedicated computer. Top10BestSEOHosting.com has recently compared ... these three companies are the best VPS hosting ...
(Date:8/31/2014)... In order to celebrate the coming of autumn, Guangdong ... and launched a big promotion. Now, all the global clients ... company’s new cars are made with great materials. FODAY Automobile ... As a matter of fact, it is providing big discounts ... in need of cheap cars can visit its website for ...
(Date:8/31/2014)... 31, 2014 In the wake of ... have proposed legislation to require mandatory labeling of GMOs ... informed purchasing decisions that affect their own health and ... advocating for stringent measures to eliminate GMOs from dietary ... Communication, Engagement” (I.C.E.) initiative with the objective of advancing ...
Breaking Medicine News(10 mins):Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 3Health News:GoDaddy, IX Web Hosting and Bluehost Are Awarded As Hosting Experts by Top10BestSEOHosting.com 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3
... majority of advanced colon cancer patients in a clinical ... drugs for managing chemotherapy side effects, such as infection, ... drug cost burdens after joining the clinical trial, according ... Institute in Boston. Although few patients reported substantial worry ...
... -- PRA International, a leading Clinical Research ... audioconference and announces it will exhibit at the 2009 ... Florida, May 30 through June 1. The audioconference, which ... 2009, and was presented by John Constant, PhD, PRA,s ...
... U.S. Food and Drug Administration (FDA) announced today that ... for Pharmaceutical Science and Clinical Pharmacology to discuss bioequivalence ... The meeting is scheduled for August 4, 2009. ... no later than two days before the meeting at ...
... 29 The J. Craig Venter Institute (JCVI) announced ... five year contract from the National Institute of Allergy ... of Health, as one of their Genomic Sequencing Centers ... Nierman, Ph.D., and Robert Strausberg, Ph.D., the contract will ...
... DeterminedToQuit.com translated to Estoydecidido.com for Latino PennsylvaniansHARRISBURG, ... Health Everette James today announced the launch ... Latino residents of Pennsylvania go tobacco free.Estoydecidido.com ... - is the Spanish version of the ...
... finds student military veterans face some unique health issuesMINNEAPOLIS/ST. ... expected to go to school this fall as a ... will need to ensure student veterans, unique needs are ... issued Friday by the University of Minnesota ...
Cached Medicine News:Health News:One in ten advanced colon cancer patients worry about prescription drug costs 2Health News:PRA International Oncology Experts at ASCO 2Health News:ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products 2Health News:ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products 3Health News:ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products 4Health News:J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases 2Health News:J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases 3Health News:PA Department of Health Launches Spanish-Language Smoking Cessation Resource Web Site 2Health News:Student Veteran Health Examined in First-of-Its-Kind Study by University of Minnesota/Minnesota State Colleges and Universities 2Health News:Student Veteran Health Examined in First-of-Its-Kind Study by University of Minnesota/Minnesota State Colleges and Universities 3
... to provide excellent protection and ease of ... being closer to an adhesive in molecular ... CoEase to maintain viscosity at high shear ... worlds for superb performance during capsulorhexis, phaco, ...
... PROVISC ophthalmic viscosurgical device is ... characterized by high molecular weight, ... tension. It provides excellent space ... is easily removed. It is ...
... permit fundus imaging and documentation of ... any need for eyepieces guarantees the ... recording and display is an entirely ... ophthalmoscope principle of modern fundus cameras. ...
... The ARIS A utomated R ... revolutionary, patented technology which provides rapid and automated ... allows eye care professionals to screen and ... in less time and at ...
Medicine Products: